TuHURA Biosciences Closes Kineta Acquisition

MT Newswires Live

Jun 30, 2025

TuHURA Biosciences (HURA) said Monday that it has completed its acquisition of Kineta.

TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.

TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.

TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.

TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.

Shares of the company were up 5% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2547921200"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547921200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547921200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547921200","market":"sg","top_or_hot":-1,"title":"TuHURA Biosciences Closes Kineta Acquisition","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences</a> (HURA) said Monday that it has completed its acquisition of Kineta.</p><p>TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.</p><p>TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.</p><p>TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.</p><p>TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.</p><p>Shares of the company were up 5% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Closes Kineta Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Closes Kineta Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-30 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences</a> (HURA) said Monday that it has completed its acquisition of Kineta.</p><p>TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.</p><p>TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.</p><p>TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.</p><p>TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.</p><p>Shares of the company were up 5% in recent Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547921200","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547921200","pubTimestamp":1751289963,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TuHURA Biosciences  said Monday that it has completed its acquisition of Kineta.TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.Shares of the company were up 5% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HURA":"TuHURA Biosciences, Inc."},"translate_title":"TuHURA Biosciences完成Kineta收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences (HURA) said Monday that it has completed its acquisition of Kineta.TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.Shares of the company were up 5% in recent Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}